<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30257">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02099617</url>
  </required_header>
  <id_info>
    <org_study_id>10-389</org_study_id>
    <nct_id>NCT02099617</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.</brief_title>
  <acronym>SENIOR</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Ceric Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ceric Sàrl</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the SENIOR study is to establish the efficacy and safety of the
      everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with
      a short dual antiplatelet therapy (DAPT) in patients ≥75 years old, suffering from stable
      angina, silent ischemia (1 month DAPT) or acute coronary syndromes (6 months DAPT) related
      to significant coronary artery disease and requiring percutaneous coronary intervention. The
      primary end point is to demonstrate that SYNERGY II in patients ≥75 years old is associated
      with a lower rate of the composite rate of major cardiovascular and cerebrovascular events
      (all-cause death, myocardial infarction, stroke, ischemia-driven target lesion
      revascularization) and a similar risk of stent thrombosis than bare metal stent at one year.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite measure of MACCEs (Major Adverse Cardiac and Cerebrovascular Events)</measure>
    <time_frame>12 months</time_frame>
    <description>all-cause death, non fatal myocardial infarction, non fatal stroke, ischemia-driven target lesion revascularization.</description>
  </primary_outcome>
  <condition>Stable Angina</condition>
  <condition>Silent Ischemia</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bare Metal Stent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent</intervention_name>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent</intervention_name>
    <arm_group_label>Bare Metal Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent</intervention_name>
    <arm_group_label>Bare Metal Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1-  Patient is ≥ 75 years old

          -  2- One or more significant coronary artery stenosis is/are present (defined as ≥70%
             by visual assessment or ≥50% with Fractional Flow Reserve &lt;0.80) or a left main
             coronary stenosis ≥50% by visual assessment) suitable for PCI with one of the
             following present:

          -  a -Silent ischemia,

          -  stress-induced myocardial ischemia ≥ 10% of myocardium in a asymptomatic patient or

          -  stress-induced myocardial ischemia &lt; 10% of myocardium AND FFR (Fractional Flow
             Reserve) ≤0.80 or

          -  b - Stable angina, in a patient with objective ischemia despite optimal medical
             therapy or

          -  c - acute coronary syndrome including: unstable angina, non ST- and ST elevation
             myocardial infarction.

          -  3- All patients must also sign informed consent as per local law and comply with all
             study process during follow up for at least one year.

        Exclusion Criteria:

          -  1- The subject is not eligible for randomization if ANY of the following is present:

          -  2- Indication for myocardial revascularization by coronary artery bypass grafting,

          -  3- Subjects unable to tolerate, obtain or comply with dual antiplatelet therapy for
             at least one month (stable angina or silent ischemia) or at least six month (acute
             coronary syndrome),

          -  4- Subjects requiring additional surgery (cardiac or non-cardiac) within one month,

          -  5- Non cardiac co-morbidities with life expectancy less than 1 year,

          -  6- Prior hemorrhagic stroke,

          -  7- Known allergy to aspirin or P2Y12 inhibitors,

          -  8- At least one contra indication to ALL the authorized P2Y12 inhibitors at the
             requested dose (in case of contra indication to only one of two of the P2Y12
             inhibitors, the investigators are allowed to use the P2Y12 inhibitors for which no
             allergy is known).

          -  9- Silent ischemia &lt;10% of the myocardium with FFR ≥0.80.

          -  10- Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Varenne</last_name>
    <phone>+33 1 58 41 42 43</phone>
    <email>olivier.varenne@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Sinnaeve</last_name>
    <email>peter.sinnaeve@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique des Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jacques Cartier Massy</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
